Figure 3

Antitumor activity of troxacitabine and gemcitabine alone (A) or in combination (B) against human pancreatic cancer (AsPc-1) xenografts. Female SCID mice were inoculated SC with 5 x 10⁶AsPc-1 cells (Day 0). Treatment, which was initiated when tumors were established (Day 14), was given on Days 14, 17, 20, and 23. Troxacitabine was given IV at 1 mg/kg (open square) and 5 mg/kg (open losange). Gemcitabine (open triangle) was administered IP at 80 mg/kg. The 1 mg/kg dose of troxacitabine was used for combination studies and drugs were given sequentially, 1h apart: gemcitabine followed by troxacitabine (closed triangle); troxacitabine followed by gemcitabine (closed square). Saline control group (closed circle) was given IP at 5 mL/kg (Days 14, 17, 20, and 23).